Research programme: clarithromycin nano-emulsion formulation - ADVENTRX Pharmaceuticals

Drug Profile

Research programme: clarithromycin nano-emulsion formulation - ADVENTRX Pharmaceuticals

Alternative Names: ANX-015; BTH 015; SDP-015

Latest Information Update: 30 Oct 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ADVENTRX Pharmaceuticals
  • Class Antibacterials; Macrolides
  • Mechanism of Action Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Bacterial infections

Most Recent Events

  • 30 Jan 2007 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top